This issue of the Bankruptcy Update focuses on Chapter 11 filings by opioid manufacturers, including Insys Therapeutics, Purdue Pharma and Mallinckrodt, as the industry faces a reckoning over its role in driving an addiction crisis in America and worldwide.

Insys Therapeutics

On June 10, 2019, Insys Therapeutics and affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. (Bankr. D. Del. Case No. 19-11292).